Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial
| العنوان: | Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial |
|---|---|
| المؤلفون: | Michael Newton, Terufumi Kato, Ki Hyeong Lee, David R. Spigel, David Planchard, Marina Chiara Garassino, Jhanelle E. Gray, Andreas Rimner, Scott J. Antonia, Euan Macpherson, Maike de Wit, Yi-Long Wu, David Vicente, Corinne Faivre-Finn, Xavier Quantin, Johan Vansteenkiste, P. Thiyagarajah, Luis Paz-Ares, Mustafa Ozguroglu, Rina Hui |
| المصدر: | Journal of Clinical Oncology. 39:8511-8511 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Durvalumab, business.industry, Internal medicine, medicine, Stage III NSCLC, business, Chemoradiotherapy, Concurrent chemoradiotherapy |
| الوصف: | 8511 Background: In the placebo-controlled Phase III PACIFIC trial of patients with unresectable Stage III NSCLC whose disease had not progressed after platinum-based concurrent chemoradiotherapy (cCRT), durvalumab improved overall survival (OS) (stratified hazard ratio [HR] 0.68; 95% confidence interval [CI] 0.53–0.87; p=0.0025; data cutoff [DCO] Mar 22, 2018) and progression-free survival (PFS) (stratified HR 0.52, 95% CI 0.42–0.65; p |
| تدمد: | 1527-7755 0732-183X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::a93b8ada7f40b0bb0c035924a23cf5e1Test https://doi.org/10.1200/jco.2021.39.15_suppl.8511Test |
| رقم الانضمام: | edsair.doi...........a93b8ada7f40b0bb0c035924a23cf5e1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|